诺瓦瓦克斯医药 NVAX 深 沪
已收盘 02-06 16:00:00 美东时间
8.25
+0.380
+4.83%
华盛通- 最 高8.31
- 今 开8.01
- 成交量 324.95万股
- 最 低 7.845
- 昨 收 7.87
- 总市值 13.41亿
- 52周最高 10.6445
- 市盈率 静 --
- 换手率 2.00%
- 52周最低 5.01
- 委 比 59.47%
- 总股本 1.62亿
- 历史最高 331.68
- 量 比 0.82
- 振 幅 5.91%
- 历史最低 3.5324
- 每 手 1
- 风险率 0.94%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pfizer Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Pfizer Inc. (NYSE:PFE) will release earnings results for its fourth quarter, be...
02-02 14:01
Novavax Stock Is Surging Monday: What's Driving The Action?
Novavax shares are up on Monday following a licensing agreement with Pfizer for the use of its Matrix-M adjuvant.
01-27 01:16
Pediatrics group defies CDC, endorses COVID, flu shots for children
The American Academy of Pediatrics updated immunization schedule for children and adolescents recommends the COVID-19 and flu vaccines, in contradiction to CDC guidelines. In January, the agency forma...
01-26 23:55
Novavax Soars as Traders Bet Big on Vaccine Future
Novavax ( ($NVAX) ) has risen by 14.48%. Read on to learn why. Novavax shares c...
01-24 22:03
美股牛股 | NUAI飙升近25%，公司在德州合作开发大型数据中心；Lucid涨逾17%
NUAI飙升近25%，公司在德州合作开发大型数据中心；美国资源大涨24%，推出全球首个关键矿物实用代币；豪华电动车公司Lucid涨逾17%，沙特业务扩张势头迅猛>>
01-22 19:22
生物科技股强势上涨，标普生物科技ETF涨2.32%
截止1月22日10点11分，上证指数涨0.54%，深证成指涨0.45%，创业板指涨0.58%。油气开采及服务、可燃冰、军工装备等板块涨幅居前。 ETF方面，标普...
01-22 10:59
Novavax Shares Rise After Licensing Deal With Pfizer
Novavax shares are trading higher Tuesday after the company announced it entered into a license agreement with Pfizer for Matrix-M adjuvant.
01-20 23:42
Novavax rises after licensing deal with Pfizer
Novavax (NVAX) shares added ~5% in the premarket on Tuesday after the COVID-19 vaccine maker reached a licensing deal with Pfizer (PFE) regarding the use of its Matrix-M adjuvant in the New York-based...
01-20 20:41
Pfizer Inks Non-Exclusive License Agreement For Novavax's Matrix-M Adjuvant for Up to Two Disease Areas, Deal Consideration Includes $30M Upfront and $500M in Milestone Payments
Under the terms of the license agreement:Novavax will receive an upfront payment of $30 million and the potential to receive up to $500 million in development and sales milestones.In addition to milestone payments,
01-20 20:18
Novavax Announces Entering into a License Agreement with Pfizer
Non-exclusive license allows for development by Pfizer to utilize Matrix-M® for up to two disease areas with its products Provides Novavax with an upfront payment of $30 million with the pot...
01-20 20:15
